Details of the Drug-Related molecule(s) Interaction Atlas

Hydroxybenzo[a]pyrene Drug Info

Benzo[a]pyren-1-ol; 1-Hydroxybenzo(a)pyrene; 1-Hydroxybenzo[a]pyrene; 13345-23-8; 3-06-00-03808 (Beilstein Handbook Reference); AC1L19Z6; BENZO(a)PYREN-1-OL; SCHEMBL3341439; ZINC5935140; BRN 2380732; CCRIS 1070; CHEMBL1907999; CTK0H6930; DTXSID40158115

Cross-matching ID

PubChem CID

25891

CAS Number

CAS 13345-23-8

TTD Drug ID

DMFSKYE

INTEDE Drug ID

DR1964

General Information of Drug (ID: DMFSKYE)

Molecule-Related Drug Atlas

Molecule Type:

DME

DOT

Drug Status:

Approved Drug(s)

Investigative Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Metabolized By UDP-glucuronosyltransferase 2B15 (UGT2B15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[3]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[4]
Lorazepam	DM84ZXF	Absence epilepsy		Approved	[5]
Hydroxybenzo(a)pyrene	DM9H5EN	N. A.	N. A.	Investigative	[1]
BRN-1980310	DMOTU4P	N. A.	N. A.	Investigative	[1]
------------------------------------------------------------------------------------

Drug(s) Metabolized By UDP-glucuronosyltransferase 2B17 (UGT2B17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[6]
Darolutamide	DMV7YFT	Prostate cancer	2C82.0	Approved	[7]
Denopamine	DM8C3GN	Cardiac disease	BA00-BE2Z	Approved	[8]
MK-7246	DMLQOF1	Respiratory disease	CB40	Phase 1	[9]
Hydroxybenzo(a)pyrene	DM9H5EN	N. A.	N. A.	Investigative	[1]
BRN-1980310	DMOTU4P	N. A.	N. A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 2B15 (UGT2B15)	DENZ6B1	UDB15_HUMAN	Substrate	[1]
UDP-glucuronosyltransferase 2B17 (UGT2B17)	DEAZDL8	UDB17_HUMAN	Substrate	[1]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
UDP-glucuronosyltransferase 2A1	OTL98JZE	UD2A1_HUMAN	Biotransformations	[2]

------------------------------------------------------------------------------------

References

1	Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos. 2006 Jun;34(6):943-9.
2	Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis. Pharmacogenet Genomics. 2011 Feb;21(2):55-65. doi: 10.1097/FPC.0b013e328341db05.
3	Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab Dispos. 2011 Apr;39(4):644-52.
4	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
5	Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005 Jun;77(6):486-94.
6	Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children. Front Pharmacol. 2016 Nov 16;7:437.
7	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
8	Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform. Drug Metab Dispos. 2005 Mar;33(3):403-12.
9	UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study. Clin Pharmacol Ther. 2012 Jul;92(1):96-102.